These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

106 related articles for article (PubMed ID: 11460000)

  • 1. A cost--utility analysis comparing second-line chemotherapy schemes in patients with metastatic breast cancer.
    Li N; van Agthoven M; Willemse P; Uyl-de Groot C
    Anticancer Drugs; 2001 Jul; 12(6):533-40. PubMed ID: 11460000
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [A medico-economic evaluation of second line chemotherapy in metastatic breast cancer: comparison between docetaxel, paclitaxel, and vinorelbine].
    Launois RJ; Reboul-Marty JM; Bonneterre J
    Bull Cancer; 1997 Jul; 84(7):709-21. PubMed ID: 9339197
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A cost-utility analysis of second-line chemotherapy in metastatic breast cancer. Docetaxel versus paclitaxel versus vinorelbine.
    Launois R; Reboul-Marty J; Henry B; Bonneterre J
    Pharmacoeconomics; 1996 Nov; 10(5):504-21. PubMed ID: 10169397
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-utility analysis of chemotherapy using paclitaxel, docetaxel, or vinorelbine for patients with anthracycline-resistant breast cancer.
    Leung PP; Tannock IF; Oza AM; Puodziunas A; Dranitsaris G
    J Clin Oncol; 1999 Oct; 17(10):3082-90. PubMed ID: 10506603
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
    Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
    Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Economic analysis of albumin-bound paclitaxel for the treatment of metastatic breast cancer.
    Dranitsaris G; Cottrell W; Spirovski B; Hopkins S
    J Oncol Pharm Pract; 2009 Jun; 15(2):67-78. PubMed ID: 19036903
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population-based pharmacoeconomic model for adopting capecitabine/docetaxel combination treatment for anthracycline-pretreated metastatic breast cancer.
    Verma S; Ilersich AL
    Oncologist; 2003; 8(3):232-40. PubMed ID: 12773745
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost effectiveness of treatment options in advanced breast cancer in the UK.
    Brown RE; Hutton J; Burrell A
    Pharmacoeconomics; 2001; 19(11):1091-102. PubMed ID: 11735676
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical data and pharmacokinetics of a docetaxel-vinorelbine combination in anthracycline resistant/ relapsed metastatic breast cancer.
    Airoldi M; Cattel L; Pedani F; Marchionatti S; Tagini V; Bumma C; Recalenda V
    Acta Oncol; 2003; 42(3):186-94. PubMed ID: 12852694
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-Effectiveness Analysis of Second-Line Chemotherapy Agents for Advanced Gastric Cancer.
    Lam SW; Wai M; Lau JE; McNamara M; Earl M; Udeh B
    Pharmacotherapy; 2017 Jan; 37(1):94-103. PubMed ID: 27870079
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Metastatic breast cancer: what are the objectives?].
    Salvini P; Ripa C; Ginanni V
    Tumori; 2000; 86(5 Suppl 1):S22-8. PubMed ID: 11195289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States.
    Garrison LP; Babigumira J; Tournier C; Goertz HP; Lubinga SJ; Perez EA
    Value Health; 2019 Apr; 22(4):408-415. PubMed ID: 30975391
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A cost effectiveness study of eribulin versus standard single-agent cytotoxic chemotherapy for women with previously treated metastatic breast cancer.
    Lopes G; Glück S; Avancha K; Montero AJ
    Breast Cancer Res Treat; 2013 Jan; 137(1):187-93. PubMed ID: 23143283
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women.
    Lairson DR; Parikh RC; Cormier JN; Chan W; Du XL
    Value Health; 2015 Dec; 18(8):1070-8. PubMed ID: 26686793
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of paclitaxel combined with vinorelbine in patients with advanced breast cancer.
    Spano JP; Bouillet T; Boaziz C; Piperno-Neumann S; Brunel P; Hennebelle F; Amsalhem P; Brunet-Pommeyrol A; Kanoui A; Morin F; Breau JL; Morere JF
    Am J Clin Oncol; 2004 Jun; 27(3):317-21. PubMed ID: 15170156
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Economic evaluation of intensive chemotherapy with prophylactic granulocyte colony-stimulating factor for patients with high-risk early breast cancer in Japan.
    Ishiguro H; Kondo M; Hoshi SL; Takada M; Nakamura S; Teramukai S; Yanagihara K; Toi M
    Clin Ther; 2010 Feb; 32(2):311-26. PubMed ID: 20206789
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biweekly docetaxel and vinorelbine in anthracycline-resistant metastatic breast cancer: a multicenter phase II study.
    Gómez-Bernal A; Cruz JJ; García-Palomo A; Arizcun A; Pujol E; Diz P; Martín G; Fonseca E; Sánchez P; Rodríguez C; del Barco E; López Y
    Am J Clin Oncol; 2003 Apr; 26(2):127-31. PubMed ID: 12714881
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vinorelbine + mitomycin C as second-line treatment of metastatic breast cancer: a two-stage phase 2 study.
    De Placido S; Lauria R; Perrone F; Vernaglia Lombardi A; Carlomagno C; Varriale E; Costanzo R; Leo L; De Laurentiis M; Bianco AR
    Oncology; 2000; 58(1):8-14. PubMed ID: 10644934
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prospective randomized trial of docetaxel versus mitomycin plus vinblastine in patients with metastatic breast cancer progressing despite previous anthracycline-containing chemotherapy. 304 Study Group.
    Nabholtz JM; Senn HJ; Bezwoda WR; Melnychuk D; Deschênes L; Douma J; Vandenberg TA; Rapoport B; Rosso R; Trillet-Lenoir V; Drbal J; Molino A; Nortier JW; Richel DJ; Nagykalnai T; Siedlecki P; Wilking N; Genot JY; Hupperets PS; Pannuti F; Skarlos D; Tomiak EM; Murawsky M; Alakl M; Aapro M
    J Clin Oncol; 1999 May; 17(5):1413-24. PubMed ID: 10334526
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Docetaxel. A pharmacoeconomic review of its use in the treatment of metastatic breast cancer.
    Lamb HM; Wiseman LR
    Pharmacoeconomics; 1998 Oct; 14(4):447-59. PubMed ID: 10344911
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.